INTRODUCTION
Male breast cancer is rare and little is known about the incidence and prognosis of this disease in Japan. Incidence and survival of male breast cancer in Osaka, Japan will be presented, described and compared with data on female breast cancer in Osaka and with data in other countries populations.
MATERIALS AND METHODS
The recent 3 decades' data of the Osaka Cancer Registry (OCR) was employed. The OCR, one of the largest population-based cancer registries in Japan, has been in operation Prefecture, excluding Osaka City, was used since these cases were actively followed up and their vital statuses at 5 years after the diagnosis were confirmed almost perfectly. Those cases registered by death certificates only, however, were excluded from the survival analysis. Cumulative 5-year survival was estimated by using the Kaplan-Meier's method. Fiveyears' relative survival was calculated by dividing the cumulative 5-year survival by corresponding 5-year expected survival, which was obtained based on the cohort survival tables prepared by the National Cancer Center, Tokyo, Japan '). In this study three categories of stage, i.e., "localized" (confined to the breast tissue), "regional" (spread to regional lymph-nodes and/or spread to immediately adjacent tissues), and "distant"
(metastasis to distant organs) were used in the analysis of stage distribution and survival by stage. This classification of stage at diagnosis is used not only in the OCR but also in most population -based cancer registries 3). The chi-square and the Mann-Whitney tests were used for comparisons of the histological type and the extent of disease distributions between males and females, respectively. Greenwood's formula was employed for testing statistical differences in 5-year survival between males and females. P-values less than 0.05 were judged as statistically significant. Statistical package software, STATA 5) was used for statistical analysis.
RESULTS

Incidence and its time-trends
The total number of male breast cancer incidence was 182 in Osaka during 1966-95. In Table 1 , the number of incidence, crude incidence rates (per 100,000 population), age-standardized rates (standardized to World population), proportion of cases with death certificate only (DCO%), and percentage of histologically verified cases (HV/R%) are presented in tenyear intervals, together with the females' data for the period of 1981-83, the middle of the total study period. The numbers of incidence and the crude incidence rates have increased in the last decades, although the age-standardized rates remained constant. During the same period, the age-standardized incidence rates for female breast cancer have increased more than 100% (11.8-23.7). DCO% and HV/R% for breast cancer in Osaka have been almost constant during this period for males (about 10% and 90 %, respectively), while corresponding indices for females decreased from 7.6% to 3.1% and increased from 76.3% to 92.1% u, Figure 1 shows the age-specific incident cases of male breast cancer in Osaka during the period of 1966-95, together with the females' data for the period of 1981-83. The mean age of those cases was 63.3 years old and the median age was 64 years old.
Comparison of incidence rates among males and females, Osaka and US SEER/Other populations Figure 2 indicates the age and sex-specific incidence rates of breast cancer in Osaka and the US whites population in 1988-92 4). Males in Osaka showed a gradual increase with age starting from 40-44 years old, while females in Osaka showed a steep increase starting at twenty years of age. These differences of incident increase starting ages and its slope for the age-specific incidence rates between males and females were also observed for the US whites. The age-specific incidence rates for Japanese females peaked around 45-49 or 50-54 years old and showed a slight decrease or plateau thereafter. These characteristics of the age-specific incidence curve of breast cancer for Japanese females were explained by the so-called birthcohort effect. For Japanese males, however, the age-specific incidence rates were not appreciably different by birth-cohort (data not shown).
In Figure 3 , scatter plots are presented, showing international correlation of the age-standardized incidence rates of breast cancer between males and females. Thirty one cancer registries' data were selected from C15 Volume VII 4) so that at least 30 male breast cancer cases could be included for plotting each registry/country data. Generally the age-standardized rates for males correlated well with those for females internationally (Pearson product-moment coefficient of correlation=0.58, P=0.0007). Two groups of populations, however, seem to be distinguishable. The first is northern, western and southern European countries (Norway, Finland, Sweden, Denmark, UK, The Netherlands, Italy, France), North America, New Zealand and Australia. The second is eastern European countries (Belarus, Latvia, Croatia, Slovakia, Yugoslavia, Czech Republic, Eastern States of Germany) and Asian countries (Osaka, China, India, Hong Kong, Philippines, Manila). The first group of populations showed much higher incidence rates of female breast cancer than the second one, and the females' rates in the first group seemed to reach a plateau for populations with highest male breast cancer risk. In the second group, the females' rates seemed to linearly correlate well with the males' rates. Age-standardized rates for males, per 100,000 Figure 3 . International correlations of the age-standardized incidence rates of breast cancer between males and females.
Distribution of histological types
In Table 2 , distribution of histological types 6) of male breast cancer cases in Osaka is presented and compared with data on 2,508 female cases diagnosed in 1981-83, the middle of the total study period. Among the 182 male breast cancer cases, detail information on histology was obtained from 97 patients. In general, distribution of the histological types was not significantly different between males and females (Chi-square=2.997 d.f.=5, P=0.7). However, proportion of the special type in males was higher than that in females (26.8% vs. 9.2%), while proportion of the scirrhous carcinoma in males was lower than that in females (11.3% vs. 15.4%).
Extent of disease and its time-trends
In Table 3 , time-trends of the extent of disease (clinical stage) are presented in ten-year periods for males, together with data for females in 1981-83. Proportions of the localized stage and the distant stage have increased in the last two decades, while percentage of the regional stage has decreased. In the total study period, distribution of the extent of disease among the male breast cancer cases did not differ significantly from that among the females (Mann-Whitney test, P=0.38), although percentage of the unknown extent of disease was higher among males than females (26.4% vs. 5.3%).
Relative 5-year survival and its comparison between males and females
In Table 4 , relative 5-year survival for the male breast cancer was presented according to the extent of disease, together with the females' data for the period of 1981-83. In total, relative 5-year survival was lower in males than in females (57.8% vs.80.1%, P=0.004). Stage-specific survivals were also consistently lower in males than in females. Statistically significant difference in the survival between males and females was observed for the regional (36.7% vs. 73.3%, P=0.003). (Number of "in situ": 1 for males, 24 for females) 
DISCUSSION
As far as the authors know, this is the first report on a population-based study on the incidence and survival of male breast cancer in Japan. Male breast cancer incidence in Osaka, Japan was suggested to belong to the lowest risk group in the world, and this coincided with females' lower risk for breast cancer in Osaka.
Although the incidence numbers and the crude incidence rates of male breast cancer in Osaka have increased, the agestandardized rates have remained constant during the last 3 decades (Table 1 ). This contrasts with more than 100% increase in the female breast cancer risk in Osaka. Since DCO% for female breast cancer in Osaka has decreased, the increase in the age-standardized incidence rates might be partly affected by improved reporting to cancer registry. This discrepancy in the time-trends of breast cancer between males and females, however, might be a reflection of different etiologies of breast cancer between the two sexes. Earlier ages at menarche and later ages at the first birth among Japanese women would be major reasons for the increase of female breast cancer in Japan 7 8) Differences in the age-specific incidence curve between males and females also suggested different determinants of breast cancer risk between males and females ( Figure 2) . The age distribution of male breast cancer in Osaka was almost the same (Mean age: 60 years) as the other papers from the US and Iceland 9,10,11,12) (Figure 1 ). An earlier and steeper increase of the age-specific incidence rates of female breast cancer could be explained by its strong estrogen dependence and breast tissue immaturity before the first delivery; while male breast cancer would be barely concerned with adipose tissue converted estrogens from adrenal androgens and accumulation of environmental risk factors 8).
The observed significant positive international correlation between males' and females' breast cancer incidences may suggest the roles of common etiological factors for breast cancer. Although there is no evidence supporting it, the so-called calorie rich dietary habits would be the most likely explanation for the international correlation. Besides the calorie rich dietary habits, reproductive histories of women i.e., later ages at the first delivery or no childbirth would have caused additional risk for breast cancer in the first group of countries and populations (northern, western and southern European countries, North America, Oceania), showing the highest female breast cancer incidence in Figure 3 13.14.15)
As for the stage and survival of male breast cancer in Osaka, the proportion of the localized stage has increased in the last 3 decades (Table 3) . However, relative 5-year survival for males was still lower than that for females (Table 4) , even though their survival (57.8%) was almost comparable to Nordic Countries* data (Denmark: 53.8%, Finland: 47.7%, Norway: 66.3%, Sweden: 63.8%) 16). The lower survival could not be explained only by the delay of diagnosis for male breast cancer in Osaka, since their stage-specific survivals were also lower than those for females 115. These results on the sex-difference in the survival were inconsistent with reports from the US and Iceland 9,10,15,16) where males' poor survival could be explained by more advanced stages at diagnosis. Percentage of scirrhous carcinoma in males was rather lower than in females in this study (Table 2) .
Finally the study limitations and the future research areas for male breast cancer should be discussed. First of all, completeness of the registration for male breast cancer incidence might not be satisfactory when compared with data from North America and Europe. Ajiki et al. 4 proposed a formula to estimate completeness of cancer registration based on DCN% 26) (proportion of the cases first notified via death certificate) and I/D (incidence to mortality) ratio, i.e., the degree of completeness %= (1-DCN%*I/D ratio) / (1-DCN%). Tentatively, DCN was defined as sum of DCO plus cases not reported but with supportive clinical information of cancer obtained through the tracing back survey, as suggested by Ajiki et al. Proportion of DCN of breast cancer in Osaka for 1993-95 was calculated as 15.4% for males and 9.4% for females, while the I/D ratio was 2.0 and 3.3, respectively. The degree of completeness was thus estimated as 81.8% for males and 76.6% for females. Although we could not estimate the degree of completeness during the whole study period, the incidence of male breast cancer in Osaka should be regarded as underestimated.
Secondly, missing data on the histological type and the extent of disease was rather high in this study. The number of breast cancer incidence was still very small. Thus the possibilities of misclassifications and random variations should be taken into consideration. Finally, the extent of disease used in this study might not be adequate for precise evaluations of clinical stage and stage-specific survival. Further studies, especially on the sex-difference in the survival, will be mandatory based on high-quality hospital-based site-specific cancer registries, which will provide us detailed information on the clinical stage and treatment.
